Sai Parenterals locks in ₹1,300-cr Australian OTC deal, 3.4x annual revenue
The 7.5-year exclusive supply contract validates the Noumed acquisition and provides transformational scale for the ₹2,586-cr market-cap company.
— 1 earlier story on Sai Parenteral's Ltd. →What's new
- Noumed signed an exclusive 7.5-year OTC supply deal with Australia's largest pharmacy network.
- Contract value of ₹1,300 cr equals 3.4x Sai Parenterals' FY26 consolidated revenue of ₹381 cr.
- Deal effective July 1, with an option to extend by three more years.
Why this matters
For a small-cap with ₹381 cr revenue, a single contract worth 3.4x that transforms revenue visibility. It validates the Noumed acquisition and positions Sai to service regulated markets at scale. Earnings upgrades are all but certain.
What we're watching
- Execution ramp-up: Noumed must deliver OTC volumes consistently over seven years.
- Debt trajectory: Sai had projected peak net debt of ₹319 cr in FY27; cash flows from this deal should accelerate deleveraging.
- Whether this opens doors for additional contracts with the same pharmacy chain or other Australian retailers.
The full read
Sai Parenterals' Australian subsidiary Noumed has signed an exclusive 7.5-year contract with the country's largest pharmacy network to supply OTC medicines. The deal is worth AUD 202 million (roughly ₹1,300 crore), or 3.4 times the Hyderabad drugmaker's entire FY26 consolidated revenue of ₹381 crore. The contract, effective July 1, also includes a three-year extension option. A deal of this scale for a small-cap pharma is rare. It validates the manufacturing capabilities that came with last November's Noumed acquisition and gives the company multi-year revenue visibility that few peers enjoy. The company had earlier projected FY27 revenue of ₹750 crore and peak net debt of ₹319 crore. This contract alone could rewrite those numbers. Execution risk remains (Noumed must deliver consistently over seven years), but the structural shift is unmistakable.
Questions answered
- How does this contract compare to Sai Parenterals' current revenue base?
- The deal is valued at roughly 3.4 times the company's FY26 consolidated revenue of ₹381 crore, making it a transformational scale event.
- What is the duration and start date of the contract?
- The agreement is for seven-and-a-half years, effective July 1, 2026, with an option to extend by an additional three years upon mutual consent.
- Which subsidiaries and customers are involved?
- The contract is between Noumed Pharmaceuticals Pty Ltd (100% subsidiary of Sai Parenterals) and Australia's largest pharmacy network. The deal covers over-the-counter medicines.
- How does this affect the company's debt levels?
- Sai Parenterals had projected peak net debt of ₹319 crore in FY27. The cash flows from this contract are expected to improve debt repayment capacity, though exact terms are undisclosed.
- Is this contract exclusive?
- Yes, the agreement is described as an exclusive long-term contract for the supply of OTC medicines to the pharmacy network.
- What does this mean for the company's revenue guidance?
- The company had earlier guided for FY27 revenue of ₹750 crore. The new contract alone could nearly double that figure, though revenue recognition will be spread over the contract life.
Sai Parenteral's Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SAIPARENT →- 1 Jul 2026 · 4:38 PM IST Sai Parenterals locks in ₹1,300-cr Australian OTC deal, 3.4x annual revenue
- 40d ago Sai Parenterals sees ₹750 cr revenue this year, will carry peak debt of ₹319 cr